Sector Expert: Alan Carr

Needham & Co

Image: Alan Carr

Alan Carr joined Needham & Company in 2006. From 2001 to 2006 Alan worked in Yale’s technology transfer group, the Office of Cooperative Research, where he out-licensed a number of technologies and therapeutic product candidates developed in Yale labs and helped establish start-up companies in the New Haven area. Prior to that he was at J. Bush & Co., a New Haven investment firm, where he covered companies in the research tool and healthcare space. His post-doctoral work was centered on the regulation of neuronal development during embryogenesis. He earned his undergraduate degree at Albion College and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Recent Interviews

Reap Biotech Profits from Overlooked Spaces: Alan Carr (6/7/12)

Within the investment community, the story goes that new antibiotics can't generate big profits and central nervous system (CNS) drugs are too difficult to develop. Investors worry they could be throwing good money after bad. Senior Biotechnology Analyst Alan Carr of Needham & Company refutes these tales and believes that product differentiation provides the formula for success. In this exclusive interview with The Life Sciences Report, Carr shares his deep industry knowledge and renders his very best ideas in the CNS, antibiotic, antiviral and metabolic spaces.

Recent Quotes

"MRK's Victrelis has substantially improved sustained virologic response rates."

The Life Sciences Report Interview with Alan Carr (6/7/12)
more >

"We saw some encouraging data from ADXN's metabotropic glutamate receptor 5 inhibitor."

The Life Sciences Report Interview with Alan Carr (6/7/12)
more >

Due to permission requirements, not all quotes are shown.